Servier
 |
|
| Private | |
| Industry | Pharmaceutical |
| Founded | (1954) |
| Founder | Jacques Servier |
| Headquarters | Suresnes, France |
| Products | Pharmaceuticals |
| Revenue | €3.9 billion (FY 2015) |
|
Number of employees
|
21,200 |
| Website | Official website |
|
Footnotes / references |
|
Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is a privately owned French pharmaceutical company that specialises in medication for cardiological and rheumatological conditions, as well as for diabetes and clinical depression. The consolidated turnover for the 2015 financial year was €3.9 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 140 countries, achieving 82% of its sales outside France. The annual sales of its ACE inhibitor, Coversyl (perindopril), in 2006 and 2007 exceeded 1 billion US dollars, making it Servier's highest-selling product.
The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 21,200 employees worldwide. The company's production sites produced 853 million drug boxes in 2013.
The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Notable products:
Other products:
Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France. Further investigations found that many previous safety alerts on that drug had been either missed or covered up, possibly through improper influence of the company.
As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
...
Wikipedia